Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Ani Pharmaceuticals (ANIP) over the last 12 years, with Q3 2025 value amounting to $71.4 million.

  • Ani Pharmaceuticals' Long-Term Deferred Tax rose 552.02% to $71.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.4 million, marking a year-over-year increase of 552.02%. This contributed to the annual value of $85.1 million for FY2024, which is 617.9% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at $71.4 million for Q3 2025, which was up 552.02% from $92.0 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $92.0 million in Q2 2025 and a low of $52.0 million during Q1 2021
  • For the 5-year period, Ani Pharmaceuticals' Long-Term Deferred Tax averaged around $77.2 million, with its median value being $81.0 million (2023).
  • In the last 5 years, Ani Pharmaceuticals' Long-Term Deferred Tax skyrocketed by 4140.48% in 2022 and then tumbled by 1982.25% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $67.9 million in 2021, then grew by 19.76% to $81.4 million in 2022, then increased by 11.49% to $90.7 million in 2023, then decreased by 6.18% to $85.1 million in 2024, then decreased by 16.11% to $71.4 million in 2025.
  • Its Long-Term Deferred Tax stands at $71.4 million for Q3 2025, versus $92.0 million for Q2 2025 and $88.5 million for Q1 2025.